Infantile Periocular Haemangioma: Optimising the Therapeutic Response

Area of Science:

• Pediatric Dermatology
• Pharmacology
• Neonatal Care

Background:

• Oral propranolol is the established first-line therapy for infantile haemangiomas.
• Its use in infants requires careful monitoring for adverse events like hypoglycemia and hypotension.
• Standard protocols involve initial test doses to ensure infant safety.

Purpose of the Study:

• To outline the recommended dosing and administration protocol for oral propranolol in infants.
• To inform healthcare providers about essential monitoring parameters and potential adverse effects.
• To guide treatment duration for optimal outcomes and prevention of rebound growth.

Main Methods:

• Administration of two initial test doses of propranolol (300 μg/kg and 650 μg/kg) with 2-hourly monitoring.
• Gradual introduction of the therapeutic dose (2 mg/kg divided t.i.d.) starting the day after test doses.
• Parental education on common adverse effects, particularly disturbed sleep.

Main Results:

• Established safe and effective dosing regimen for infantile haemangiomas.
• Identified disturbed sleep as the most frequent adverse effect requiring parental awareness.
• Demonstrated the importance of a structured approach to propranolol initiation in infants.

Conclusions:

• Oral propranolol requires a controlled initiation with specific test doses and monitoring.
• Awareness of potential adverse effects, such as disturbed sleep, is crucial for successful management.
• A treatment duration of up to one year is recommended to prevent rebound growth and treatment restarts.